HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that on October 30, 2024, it received notice from The Nasdaq Hearings Panel that the Company has been granted an exception until March 11, 2025, to regain compliance with the minimum bid price requirement in Listing Rule 5550(a)(2).
PrimeTimeFortySix : 脳からの転移ですか? 脳への転移ですか??
Jaguar8 スレ主 PrimeTimeFortySix : 脳に転移しています。